Edition:
United States

Consumer Goods & Retail Headlines

Cholesterol drug maker pays $4.1 mln to settle fraud charges-SEC

Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, will pay $4.1 million to settle charges it misled investors about how many patients purchased Juxtapid, a drug used to treat a genetic condition that leads to high cholesterol, the top U.S. securities regulator said on Friday.

Earlier
Photo

Trump clashes with sports world over player protests, invitation

(Attention to language that might offend some readers in paragraphs 3-4) | Video